Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 9/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.39 |
| ▸ | ACP1 | P24666 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075973 | 0.91 | FEN1 (0.39) | FEN1ALOX5APACP1MCHR1HTR2B | |
| SCHEMBL26075355 | 0.90 | PDE2A (0.45) | FEN1ALOX5APMCHR1HTR2BPDE2A | |
| SCHEMBL26075292 | 0.89 | FEN1 (0.41) | FEN1ALOX5APACP1MCHR1HTR2B | |
| SCHEMBL26075361 | 0.89 | PDE2A (0.47) | FEN1ALOX5APMCHR1HTR2BPDE2A | |
| SCHEMBL26075353 | 0.89 | PDE2A (0.47) | FEN1ALOX5APMCHR1HTR2BPDE2A | |
| SCHEMBL26075373 | 0.89 | HTR2B (0.40) | FEN1ALOX5APACP1MCHR1HTR2B | |
| SCHEMBL26075363 | 0.89 | PDE2A (0.47) | FEN1ALOX5APMCHR1HTR2BPDE2A | |
| SCHEMBL26075359 | 0.89 | PDE2A (0.47) | FEN1ALOX5APMCHR1HTR2BPDE2A | |
| SCHEMBL26075327 | 0.88 | SQOR (0.42) | ACP1SQOR | |
| SCHEMBL26075335 | 0.88 | ACP1 (0.50) | FEN1ALOX5APACP1NT5EPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | FEN1 3899/4885ALOX5AP 821/4885ACP1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.